08:30 AM EDT, 05/14/2024 (MT Newswires) -- Profound Medical ( PROF ) said Tuesday that it received US Food and Drug Administration clearance for its TULSA-AI Contouring Assistant for use with its TULSA-PRO system to treat prostate disease.

The medical device company said that TULSA uses pixel-by-pixel precision and sound technology to kill diseased prostate tissue without damaging urinary or sexual functions in a single session.

The Contouring Assistant employs machine learning to help in targeting damaged tissue.

Shares of the company were up more than 17% in recent Tuesday premarket activity.

Price: 8.98, Change: +1.33, Percent Change: +17.39